Overview

A Randomized Study to Compare the Efficacy and Safety of Belotecan and Topotecan as Monotherapy for Sensitive-Relapsed Small Cell Lung Cancer

Status:
Completed

Trial end date:
2018-03-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy and safety of Belotecan administered 5 days every 3 weeks in comparison to Topotecan in Patients with relapsed small cell lung cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Chong Kun Dang Pharmaceutical

Treatments:

Belotecan
Camptothecin
Topotecan